Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EHang Holdings Ltd - ADR (EH) vs Cassava Sciences Inc (FLNA) Price & Performance

EHang Holdings Ltd - ADRTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

EHang Holdings Ltd - ADR vs Cassava Sciences Inc — how do they compare? EHang Holdings Ltd - ADR trades at $5.79 (market cap $435.35M), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: EHang Holdings Ltd - ADR is far larger — about 9.1× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.

EHFLNA
Market Cap
$435.35M$47.75M
Sector
IndustrialsHealth
52-Week High
$19.44$4.64
52-Week Low
$4.90$0.87
Enterprise Value
$374.58M-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EHang Holdings Ltd - ADR

EHang Holdings (EH) trades at $5.74, up 7.69% in the last session, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, flat year-over-year, but with a significant net loss of $276 million, reflecting ongoing profitability challenges despite a high gross margin of 61.53%. Recent news highlights operational progress, including the first pilotless eVTOL flight in Central Asia, but the stock remains volatile amid sector-wide pressures.

The outlook for EH is highly speculative, with substantial execution risks and negative earnings overshadowing long-term potential in the advanced air mobility market. Analyst sentiment is divided, with a consensus price target of $6.97 offering limited upside, while institutional ownership trends and cash flow volatility underscore the high-risk nature of the investment.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA